Overview
Endocrinology Regulatory Landscape
The regulatory environment for endocrinology therapies involves specialized requirements from FDA Division of Diabetes, Lipid Disorders, and Obesity, EMA Endocrinology Working Party, PMDA Metabolic Products Review. This guide maps each requirement to ArcaScience's platform capabilities, demonstrating how AI-driven benefit-risk analysis aligns with and accelerates regulatory compliance.
Regulatory Requirements
Key Requirements by Agency
FDA Requirements
- ✓ Cardiovascular outcome trial requirements for diabetes drugs
- ✓ Obesity drug development guidance
- ✓ Diabetes clinical trial design requirements
- ✓ Hypoglycemia assessment guidance
- ✓ Post-marketing CVOT requirements
EMA Requirements
- ✓ Guideline on clinical investigation of diabetes
- ✓ Cardiovascular assessment requirements
- ✓ Obesity drug development requirements
- ✓ PSUR expectations for metabolic products
PMDA Requirements
- ✓ Japan-specific diabetes drug safety monitoring
- ✓ Cardiovascular assessment requirements for diabetes drugs
- ✓ Post-marketing metabolic surveillance
ArcaScience Alignment
How ArcaScience Maps to Endocrinology Requirements
Data Coverage
Endocrinology-specific data from 47+ global sources, pre-harmonized and validated for regulatory submissions.
AI Models
Endocrinology-trained AI models for adverse event classification, signal detection, and benefit quantification with regulatory validation.
Regulatory Outputs
Pre-formatted outputs aligned with FDA Division of Diabetes, Lipid Disorders, and Obesity and EMA Endocrinology Working Party submission requirements.
Download
Get the Full Endocrinology Regulatory Landscape
Complete the form below to receive the document via email.
Related Resources